Skip to Content

Posts tagged with "Academia (vs. Industry)"

  • Academia (vs. Industry)

    Francis Collins Knows Why We Don’t Have An Ebola Vaccine

    NIH Director Francis Collins has been saying that if only the agency’s budget hadn’t been cut, that we would already have an Ebola vaccine. He tried this line out during recent Congressional testimony, and apparently liked it enough that he expanded on it in an article for the Huffington Post. Collins’ statements have been fodder… Read More
  • Academia (vs. Industry)

    Different Screening, Different Thermodynamics?

    Chris Lipinski and the folks at Collaborative Drug Discovery send word of an interesting webinar that will take place this coming Wednesday (October 22nd) at 2 PM EST. It’s on enthalpic and entropic trends in ligand binding, and how various screening and discovery techniques might bias these significantly. Here’s the registration page i… Read More
  • Academia (vs. Industry)

    PAINS Go Mainstream

    Well, I’m back in the Eastern Time Zone after flying in from Basel (and Amsterdam) yesterday. And the first thing I wanted to mention was this article from Jonathan Baell and Michael Walters inNature, on the PAINS compounds. It’s good to see the journal cover this issue (and I was impressed that they got New… Read More
  • Academia (vs. Industry)

    A Day of Irreproducibility In Cambridge

    I wanted to mention that there’s an interesting symposium on “Irreproducibility in Target Validation” taking place at Novartis (Cambridge, MA) next month, October 23. This is a topic that many an industrial biopharma researcher can relate to, and as academic centers get into more drug research, they’re joining the rueful par… Read More
  • Academia (vs. Industry)

    Are Your Compounds Ugly? Do You Know?

    A reader sends along this paper, on some small molecules targeting the C2 domain of coagulation factor VIII. It illustrates some points that have come up around here over the years, that’s for sure. The target is not a particularly easy one: a hit would have to block the interaction of that protein domain with… Read More
  • Academia (vs. Industry)

    The Prospects of an Academic Job

    Over the years, there have been more comments than anyone can count here on the often-grim employment picture for chemistry and biology employment in biopharma. Plenty of people here (myself included) can speak from experience. But we should also remember that the academic job market in the biomedical sciences is in awful shape, too, unfortunately. Read More
  • Academia (vs. Industry)

    Where the Talent Comes From

    I occasionally talk about the ecosystem of the drug industry being harmed by all the disruptions of recent years, and this post by Bruce Booth is exactly the sort of thing that fits that category. He’s talking about how much time it takes to get experience in this field, and what’s been happening to the… Read More
  • Academia (vs. Industry)

    Changing A Broken Science System

    Here’s a suggestion for a total reform of the graduate student/postdoc system of scientific labor and training. It’s from a distinguished list of authors, and appears in a high-profile journal, and it says without any equivocation that the system we have is in major trouble: In the context of such progress, it is remarkable that… Read More
  • Academia (vs. Industry)

    A Reply on Academic Alzheimer’s Research

    One of the authors of a paper I commented on has shown up in the comments section to that post, and I wanted to highlight his reply out here on the front page of the blog. Here’s J. R. Brender, from the Michigan side of the authorship: Hi. I appreciate the comments the given about… Read More
  • Academia (vs. Industry)

    An All-In-One Alzheimer’s Paper

    A reader sent along this paper that’s come out recently in JACS, from a Michigan/South Korea/UCSB team of researchers. It’s directed towards a possible therapeutic agent for Alzheimer’s disease. They’re attempting to build a molecule that binds beta-amyloid, coordinates metals, and has antioxidant properties all at the same… Read More
...345...